Table 4.
Antimicrobial | Drug name | Company | Class | Source | Mol Wt | Application | MOA | Dosing | References |
---|---|---|---|---|---|---|---|---|---|
Colistin (Polymyxin E) | Coly-Mycin | Generic | Lipopeptide | Bacillus colistinus | 1155.4 | Antibacterial; Gram - | Membrane disruption | IV, IM and Inhalation | Karaiskos et al., 2017 |
Dalbavancina | Dalvance | Durata Therapeutics | Lipoglycopeptide | Semi-synthetic | 1816.7 | Antibacterial; Gram + | Cell wall biosynthesis | IV | Bassetti et al., 2018 |
Daptomycin | Cubicin | Merck (Cubist) | Lipopeptide | Streptomyces roseosporus | 1620.6 | Antibacterial; Gram + | Membrane disruption | IV | Gonzalez-Ruiz et al., 2016 |
Gramicidin D | NA | Generic | Linear peptides | Bacillus brevis | 1882.2 | Antibacterial; Gram + | Membrane disruption | Topical | Burkhart et al., 1999 |
Gramicidin S | NA | Generic | Cyclic peptide | Bacillus brevis | 1141.4 | Antibacterial; Gram + and - | Membrane disruption | Topical | Mogi and Kita, 2009 |
Oritavancinb | Orbactiv | Melinta Therapeutics | Lipoglycopeptide | Semi-synthetic | 1793.1 | Antibacterial; Gram + | Cell wall biosynthesis | IV | Saravolatz and Stein, 2015 |
Polymyxin B | NA | Generic | Lipopeptide | Bacillus polymyxa | 1203.5 | Antibacterial; Gram - | Membrane disruption | IV and IM | Rigatto et al., 2019 |
Teicoplanin | Targocid | NPS Pharma | Glycopeptide | Actinoplanes teichomyceticus | 1879.6 | Antibacterial; Gram + | Cell wall biosynthesis | IV and IM | Campoli-Richards et al., 1990 |
Telavancinb | Vibativ | Theravance | Lipoglycopeptide | Semi-synthetic | 1755.7 | Antibacterial; Gram + | Cell wall biosynthesis | IV | Higgins et al., 2005 |
Vancomycin | NA | Generic | Glycopeptide | Streptomyces orientalis | 1449.3 | Antibacterial; Gram + | Cell wall biosynthesis | Oral and IV | Alvarez et al., 2016 |
Anidulafungin | Eraxis | Pfizer | Echinocandin (lipopeptide) | Semi-synthetic | 1140.2 | Antifungal | Cell wall biosynthesis | IV | Mayr et al., 2011 |
Caspofungin | Cancidas | Merck | Echinocandin (lipopeptide) | Semi-synthetic | 1093.3 | Antifungal | Cell wall biosynthesis | IV | Song and Stevens, 2016 |
Micafungin | Mycamine | Astellas | Echinocandin (lipopeptide) | Semi-synthetic | 1270.3 | Antifungal | Cell wall biosynthesis | IV | Scott, 2012 |
IV, Intravenous; IM, Intramuscular; NA, Not applicable;
Dalbavancin is a semi-synthetic derivative of Teicoplanin;
Oritavancin and Telavancin are semi-synthetic derivatives of Vancomycin.